Probiotics may alleviate symptoms of hay fever, which may be related to bacteria in our gut and nose.

Published Date: 26 Apr 2023

The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.

Read Full News

Latest News

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

HCPLive 5 Stories in Under 5: Week of 10/05 Victoria Johnson

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Latest News

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

News All Time

GLP-1 RAs Reduce Anemia Risk in Patients with Celiac Disease Abigail Brooks, MA

GLP-1 RA use was linked to a significant survival benefit and reduced risk of iron deficiency anemia in patients with celiac disease.

1 in 10 People Without Celiac Disease Report Gluten or Wheat Sensitivity Chelsie Derman

Study finds non-celiac gluten or wheat sensitivity is more common in women and linked to IBS, anxiety, and depression.

Closing the Diagnostic Gap in Eosinophilic Esophagitis, With Walker Redd, MD Walker Redd, MD

Redd reviews real-world data highlighting low rates of biopsies performed among patients with esophageal food impaction-related emergency department visits.

Don't let food poisoning crash your Thanksgiving dinner

Thanksgiving is a time for family, friends and feasting. However, amid the joy of gathering and indulging in delicious food, it is essential to keep food safety in mind. Foodborne illnesses can quickly put a damper on your ...

How the gut builds long-lasting immunity after viral infections

A new study led by University of Toronto researchers has shown that immune cells in the gut follow an atypical pathway to produce antibodies that provide long-term protection against viruses.

New drug offers hope to bladder cancer patients

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.

Medications change our gut microbiome in predictable ways, research reveals

Our gut microbiome is made up of trillions of bacteria and other microbes living in our intestines. These help our bodies break down food, assist our immune system, send chemical signals to our brain, and potentially serve ...

Researchers find simple way to make kale healthier by pairing it with oil-based dressings

Think that kale salad you're eating is a superfood? Without the right ingredient it might not be living up to its hype. But don't worry.

How weakness in cell structure affects the host–microbiome relationship

Cells have an internal skeleton that maintains their structure and also drives their movement. Known as the cytoskeleton, this scaffold is composed of a network of dynamic filaments made of a protein called actin.

AI analyzes multiple physicians' notes to improve diagnosis of complex liver condition

Taking a page from market research tactics, UC San Francisco experts are studying whether artificial intelligence (AI) can improve diagnosis of a complex liver condition by using the clinical notes of multiple providers.

Scientists map the cells that drive Crohn's disease fistulas

Scientists at the University of Oxford, have identified how rare populations of abnormal cells drive the formation and persistence of fistulas—painful, tunnel-like tracts that develop in around 30% of people with Crohn's ...

Ultra-processed foods tied to higher rates of early-onset colorectal cancer precursors in adults

Colorectal cancer used to be associated with old age, but diagnoses have become increasingly common in adults aged 50 or younger particularly in high-income countries like the United States. The reason for this trend is unclear, ...

Pill-induced esophagitis: Why your medication could be damaging your throat and what to do about it

Every year, people around the world take an astonishing 3.8 trillion doses of medicine. Most of these medicines are swallowed rather than injected or inhaled, because the oral route is the easiest, safest and most familiar ...

Can't sleep? Your microbiome may play a role

Sleep is a hot commodity—we want it, we need it, but most of us aren't getting enough of it.

Plants adapting to climate change may help IBD treatment

James Cook University (JCU) researchers have discovered that the same chemical compounds produced by mountain-top plants to help them survive climate change in North Queensland may also hold promise for treating inflammatory ...

High-risk individuals who have mild dilation of pancreatic duct have increased risk for pancreatic cancer, study finds

Pancreatic ductal adenocarcinoma is projected to become the second-leading cause of cancer death in the United States by 2030, according to the National Institutes of Health (NIH). The International Cancer of the Pancreas ...

Recommended News For You

New tumor therapy approach reduces costs and side effects while increasing accessibility

Squeezing through tiny blood vessels may trigger melanoma cells to spread

Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

Drug-chemo combo increases cancer treatment efficacy

Having a tattoo could increase your risk of developing lymphoma.

After targeted agents, a novel bispecific in EGFR-mutant lung cancer improves PFS.

Recommended Articles For You

The Power of White Blood Cells: How They Help Keep Us Healthy 

Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA 

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study 

New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Parkinson patient's gait is restored by a spinal cord stimulator.

2.

A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.

3.

Next Day Mood Is Affected by Ability to Recover From Work.

4.

Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness

5.

Children with cancer experience much less pain at home when using a pain monitoring app.

1.

Unlocking the Potential of Leukemia Treatment: A New Hope for Patients

2.

Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology

3.

New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma 

4.

The Lowdown on Darbepoetin: Understanding Its Uses and Side Effects 

5.

The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI

2.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion

3.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

4.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

5.

Efficient Management of First line ALK-rearranged NSCLC - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot